about
Tumor necrosis factor-alpha inhibitor treatment for sarcoidosisMedical management of uveitis - current trendsBarrier dysfunction of the corneal endothelium in response to TNF-alpha: role of p38 MAP kinase.Emerging role of antioxidants in the protection of uveitis complications.Infliximab therapy for hepatic and intestinal sarcoidosis.Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease.TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakageEfficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsAdalimumab in the therapy of uveitis in childhoodAdalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.Biologic therapies for inflammatory eye disease.Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.Birdshot uveitis: current and emerging treatment optionsUpdate on the use of systemic biologic agents in the treatment of noninfectious uveitis.A review and update on orphan drugs for the treatment of noninfectious uveitisEx-vivo tolerogenic F4/80⁺ antigen-presenting cells (APC) induce efferent CD8⁺ regulatory T cell-dependent suppression of experimental autoimmune uveitis.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Update on the therapy of Behçet disease.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Biological agents for the treatment of uveitis.Biologic agents in inflammatory eye disease.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.Approaches to immunosuppression in Behçet's disease.Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review.Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.Elevated cAMP opposes (TNF-alpha)-induced loss in the barrier integrity of corneal endotheliumBehcet's disease: systemic and ocular manifestations.Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.Adalimumab: a new modality for Behçet's disease?[Behcet's disease--ophthalmological and general aspects: Part 2: Therapy].Infliximab and adalimumab for uveitis.Oxidative stress and reactive oxygen species: a review of their role in ocular disease.Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome.A Pilot Study on Ocular Safety and Efficacy of Infliximab as an Antifibrotic Agent After Experimental Glaucoma Filtration Surgery.[Anti-TNF-α treatment for uveitis. Analysis of the current situation].Extraintestinal Manifestations of Inflammatory Bowel Disease.Evaluation of intravitreal injection of pentoxifylline in experimental endotoxin-induced uveitis in rabbits
P2860
Q24652971-D2F22DC9-FF13-43D8-89B6-365DB5A2136FQ27003399-6D0DBD49-3DA9-4CF1-8FC8-FD5E8176E297Q33845168-4CCBA599-28E6-4B6F-99A0-7C2541C9C0E1Q34887046-5F4469CE-FB53-429E-9E67-FBFC103964B6Q34996785-D431E4B5-3B81-4C11-A7D4-E977924A9428Q35001001-BEECA80B-46F3-40E3-8808-C658074EBAB6Q35642213-E70AB168-B2C6-47FC-85DF-81EFEDD2AD45Q35699360-386A7F71-567F-45E6-8606-0D2299EC7ACEQ35763157-A39B1F32-D870-4F79-AF39-784A15B91C7FQ35904466-B075EC56-80EC-4D75-899B-30BD569C6C5FQ36501675-F36BA401-0AD1-4A3A-B6A8-BC914D5565F8Q36849136-21427C21-EBA1-41CA-AF5E-4EE0D7523E97Q37412317-9ACB21B7-84E1-4D79-AAF1-E43CFA8C0556Q37600483-1407EBD2-A6B0-4158-B073-CF95B019853FQ37632096-2BB3B052-6598-4FC6-8F95-AC433B1DFEE6Q37644169-4710A402-97F8-41BD-BF9C-C63A3A41623FQ37650221-0E5615D6-DB2D-4572-8C32-B7B4F3F08B13Q37712230-B4F692AF-40BD-403F-B135-2D3DCE1F8FE8Q37756167-54BCCDFA-BE42-4B4E-88FC-2CFD90281306Q37984565-AA759B6E-FB90-4444-A317-8913B87383D1Q37997772-C2AB2D22-F112-4297-9614-3C4587AAC807Q38074446-03D324B9-06AF-4B89-9F87-42C1CB3A7A7FQ38119551-4B37BC01-253C-46AC-A244-FD70B16E3C21Q38977592-ED2A5FEE-0A79-4D35-96C6-BE1152A7B209Q40488997-B23F79CB-2493-4CEC-9E50-9F3AA84AB4DCQ41942146-D8D99839-F4EF-4B06-A265-E4D4788E6ED6Q42181745-132C252A-0DA3-4D5F-9BF6-D30B5C874A63Q42444525-431F6709-1F28-46A0-AABA-92867B0AC2ACQ42844975-CDAB507B-79AA-41B4-9AB8-E9F558079EE5Q44524653-73190E3C-80FA-40D0-98A9-BF1C032C6CBCQ46040860-40836C1A-46A2-40B0-B6A4-B44CA04BC6C8Q46248374-71991589-17A4-4B8E-86B1-EC9A66BD6CFFQ47093888-A0DB59AA-FD9D-47F1-ACA4-E1D4CE0B595AQ47162808-EAF49EC2-FC61-4903-9E7F-A17368702268Q52899661-82E830F7-BA8B-4396-A256-032F005CF8FFQ55206226-D4D8A524-3813-427E-B219-5EB4C7563272Q57825206-95ACC1AA-A63B-46E2-BF03-AD4B017DCF3D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Anti-TNF-alpha therapy for sight threatening uveitis.
@ast
Anti-TNF-alpha therapy for sight threatening uveitis.
@en
type
label
Anti-TNF-alpha therapy for sight threatening uveitis.
@ast
Anti-TNF-alpha therapy for sight threatening uveitis.
@en
prefLabel
Anti-TNF-alpha therapy for sight threatening uveitis.
@ast
Anti-TNF-alpha therapy for sight threatening uveitis.
@en
P2093
P2860
P356
P1476
Anti-TNF-alpha therapy for sight threatening uveitis.
@en
P2093
E W Lindstedt
G S Baarsma
P M van Hagen
R W A M Kuijpers
P2860
P304
P356
10.1136/BJO.2003.037192
P407
P577
2005-05-01T00:00:00Z